Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 6/2018

01-06-2018 | Guide Line

Chinese guidelines for treatment of adult primary immune thrombocytopenia

Authors: Xin-guang Liu, Xiao-chuan Bai, Fang-ping Chen, Yun-feng Cheng, Ke-sheng Dai, Mei-yun Fang, Jian-Ming Feng, Yu-ping Gong, Tao Guo, Xin-hong Guo, Yue Han, Luo-jia Hong, Yu Hu, Bao-lai Hua, Rui-bing Huang, Yan Li, Jun Peng, Mi-mi Shu, Jing Sun, Pei-yan Sun, Yu-qian Sun, Chun-sen Wang, Shu-jie Wang, Xiao-min Wang, Cong-ming Wu, Wen-man Wu, Zhen-yu Yan, Feng-e Yang, Lin-hua Yang, Ren-Chi Yang, Tong-hua Yang, Xu Ye, Guang-sen Zhang, Lei Zhang, Chang-cheng Zheng, Hu Zhou, Min Zhou, Rong-fu Zhou, Ze-ping Zhou, Hong-li Zhu, Tie-nan Zhu, Ming Hou

Published in: International Journal of Hematology | Issue 6/2018

Login to get access

Abstract

Primary immune thrombocytopenia (ITP) is a bleeding disorder commonly encountered in clinical practice. The International Working Group (IWG) on ITP has published several landmark papers on terminology, definitions, outcome criteria, bleeding assessment, diagnosis, and management of ITP. The Chinese consensus reports for diagnosis and management of adult ITP have been updated to the 4th edition. Based on current consensus positions and new emerging clinical evidence, the thrombosis and hemostasis group of the Chinese Society of Hematology issued Chinese guidelines for management of adult ITP, which aim to provide evidence-based recommendations for clinical decision making.
Appendix
Available only for authorised users
Literature
1.
Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174–80.PubMed
2.
Terrell DR, Beebe LA, Neas BR, Vesely SK, Segal JB, George JN. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012;87(9):848–52.CrossRefPubMedPubMedCentral
3.
Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–15.CrossRefPubMed
4.
British Committee for Standards in Haematology General Haematology. Task F: guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574–96.CrossRef
5.
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.CrossRefPubMed
6.
Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.CrossRefPubMed
7.
Chinese Society of Hematology GoTaH. Consensus Of Chinese Specialists On the diagnosis and treatment of the adult primary immune thrombocytopenia. Chin J Hematol. 2012;33(11):975–7.
8.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–93.CrossRefPubMed
9.
Thrombosis, Hemostasis Group HSCMA. Consensus of Chinese experts on diagnosis and treatment of adult primary immune thrombocytopenia (version 2016). Zhonghua Xue Ye Xue Za Zhi. 2016;37(2):89–93.
10.
Wang XQ. Prospective clinical study of diagnosis and classification for 282 cases with primary myelodysplastic syndrome. Zhonghua Xue Ye Xue Za Zhi. 2006;27(8):546–9.PubMed
11.
Kuendgen A, Matsuda A, Germing U. Differences in epidemiology of MDS between Western and Eastern countries: ethnic differences or environmental influence? Leuk Res. 2007;31(1):103–4.CrossRefPubMed
12.
Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of aplastic anemia (2017. Zhonghua Xue Ye Xue Za Zhi. 2017;38(1):1–5.
13.
Salama A, Rieke M, Kiesewetter H, von Depka M. Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature. Ann Hematol. 2009;88(1):11–5.CrossRefPubMed
14.
Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127(3):296–302 (quiz 370).CrossRefPubMed
15.
Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109(4):1401–7.CrossRefPubMed
16.
Matschke J, Muller-Beissenhirtz H, Novotny J, Vester I, Hertenstein B, Eisele L, et al. A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naive adult patients with immune thrombocytopenia: EIS 2002 study. Acta Haematol. 2016;136(2):101–7.CrossRefPubMed
17.
Ben-Yehuda D, Gillis S, Eldor A. Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematol. 1994;91(1):1–6.CrossRefPubMed
18.
Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the cooperative latin american group on hemostasis and thrombosis. Blood. 1984;64(6):1179–83.PubMed
19.
Wang S, Yang R, Zou P, Hou M, Wu D, Shen Z, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol. 2012;96(2):222–8.CrossRefPubMed
20.
Wang M, Liu YF, Sun H, Xie XS, Ma J, Gan SL, et al. Clinical analysis of recombinant human thrombopoietin for treatment of 46 adult patients with newly diagnosed primary immune thrombocytopenia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(2):531–5.PubMed
21.
Liu X, Huang Y, Liu W, Chen Y, Xue F, Zhang L, et al. Clinical analysis of recombinant human thrombopoietin for 92 adults with severe primary immune thrombocytopenia. Zhonghua Xue Ye Xue Za Zhi. 2015;36(4):312–5.PubMed
22.
Hua B, Zhao Y, Wang S, Zhu T, Zhao Y. Development of recombinant human thrombopoietin antibodies following multi-dosing, subcutaneously medication in thrombocytopenic patients. Chin J Thromb Hemostasis. 2005;11(2):59–61.
23.
Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–47.CrossRefPubMed
24.
Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2009;373(9664):641–8.CrossRef
25.
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet (London, England). 2011;377(9763):393–402.CrossRef
26.
Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537–45.CrossRefPubMed
27.
Yang R, Li J, Jin J, Huang M, Yu Z, Xu X, et al. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol. 2017;176(1):101–10.CrossRefPubMed
28.
Gonzalez-Lopez TJ, Alvarez-Roman MT, Pascual C, Sanchez-Gonzalez B, Fernandez-Fuentes F, Jarque I, et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol. 2016;97(3):297–302.CrossRefPubMed
29.
Mazza P, Minoia C, Melpignano A, Polimeno G, Cascavilla N, Di Renzo N, et al. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol. 2016;95(2):239–44.CrossRefPubMed
30.
31.
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (London, England). 2008;371(9610):395–403.CrossRef
32.
Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161–71.CrossRefPubMed
33.
George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009;144(3):409–15.CrossRefPubMed
34.
Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag DR, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889–99.CrossRefPubMed
35.
Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118(16):4338–45.CrossRefPubMed
36.
Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411–23.CrossRefPubMed
37.
Cines DB, Gernsheimer T, Wasser J, Godeau B, Provan D, Lyons R, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol. 2015;102(3):259–70.CrossRefPubMed
38.
Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25–33.CrossRefPubMed
39.
Godeau B, Porcher R, Fain O, Lefrere F, Fenaux P, Cheze S, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999–1004.CrossRefPubMed
40.
Arnold DM, Heddle NM, Carruthers J, Cook DJ, Crowther MA, Meyer RM, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012;119(6):1356–62.CrossRefPubMed
41.
Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol. 2012;158(3):386–98.CrossRefPubMed
42.
Patel VL, Mahevas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–95.CrossRefPubMedPubMedCentral
43.
Bussel JB, Lee CS, Seery C, Imahiyerobo AA, Thompson MV, Catellier D, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than 2 years duration. Haematologica. 2014;99(7):1264–71.CrossRefPubMedPubMedCentral
44.
Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viallard JF, Cheze S, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228–36.CrossRefPubMed
45.
Ghanima W, Khelif A, Waage A, Michel M, Tjonnfjord GE, Romdhan NB, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2015;385(9978):1653–61.CrossRef
46.
Fianchi L, Rossi E, Murri R, De Stefano V, Pagano L, Leone G. Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Ann Hematol. 2007;86(3):225–6.CrossRefPubMed
47.
Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93(6):930–3.CrossRefPubMed
48.
Zhou H, Xu M, Qin P, Zhang HY, Yuan CL, Zhao HG, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015;125(10):1541–7.CrossRefPubMedPubMedCentral
49.
Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623–34.CrossRefPubMed
50.
Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005;90(1):72–7.PubMed
51.
Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121(23):4782–90.CrossRefPubMedPubMedCentral
52.
Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol. 1990;74(2):223–8.CrossRefPubMed
53.
Emilia G, Morselli M, Luppi M, Longo G, Marasca R, Gandini G, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002;99(4):1482–5.CrossRefPubMed
54.
Maloisel F, Andres E, Zimmer J, Noel E, Zamfir A, Koumarianou A, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004;116(9):590–4.CrossRefPubMed
55.
Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005;75(1):60–4.CrossRefPubMed
56.
George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3–40.PubMed
57.
Szczepanik AB, Sikorska A, Slomkowski M, Konopka L. The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients. Int J Lab Hematol. 2007;29(5):347–51.CrossRefPubMed
58.
Xiao S, Liu Q, Hou M. Comparative study between two bleeding grading systems of primary immune thrombocytopenia. Zhonghua Xue Ye Xue Za Zhi. 2017;38(5):394–8.PubMed
Metadata
Title
Chinese guidelines for treatment of adult primary immune thrombocytopenia
Authors
Xin-guang Liu
Xiao-chuan Bai
Fang-ping Chen
Yun-feng Cheng
Ke-sheng Dai
Mei-yun Fang
Jian-Ming Feng
Yu-ping Gong
Tao Guo
Xin-hong Guo
Yue Han
Luo-jia Hong
Yu Hu
Bao-lai Hua
Rui-bing Huang
Yan Li
Jun Peng
Mi-mi Shu
Jing Sun
Pei-yan Sun
Yu-qian Sun
Chun-sen Wang
Shu-jie Wang
Xiao-min Wang
Cong-ming Wu
Wen-man Wu
Zhen-yu Yan
Feng-e Yang
Lin-hua Yang
Ren-Chi Yang
Tong-hua Yang
Xu Ye
Guang-sen Zhang
Lei Zhang
Chang-cheng Zheng
Hu Zhou
Min Zhou
Rong-fu Zhou
Ze-ping Zhou
Hong-li Zhu
Tie-nan Zhu
Ming Hou
Publication date
01-06-2018
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 6/2018
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2445-z

Other articles of this Issue 6/2018

International Journal of Hematology 6/2018 Go to the issue

Case Report

10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation

Original Article

Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan

Original Article

Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms

Progress in Hematology

Guest editorial: Regulatory signaling in normal and abnormal hematopoiesis

Case Report

Three coexisting lymphomas in a single patient: composite lymphoma derived from a common germinal center B-cell precursor and unrelated discordant lymphoma

Original Article

Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits